Skip to content
Study details
Enrolling now

Contrast-Enhanced Ultrasound for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation

john eisenbrey
NCT IDNCT05641935ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

210

Study length

about 4.8 years

Ages

18+

Locations

1 site in PA

What this study is about

This trial is testing if contrast-enhanced ultrasound (CEUS) can help diagnose kidney cancer that has returned after treatment. CEUS may assist in finding and monitoring long-term recurrence of renal cell cancer following cryo or microwave ablation.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Electronic Health Record Review
  • 2.Take Sulfur Hexafluoride Lipid Microspheres
  • 3.Undergo Computed Tomography
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
topical

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Diagnostic Agent (Ultrasound Contrast Activity)

Drug routes

topical (Topical Lotion)

Endpoints

Secondary: Improvement of diagnostic imaging using 2D contrast-enhanced ultrasound (CEUS) with magnetic resonance/ computed tomography fusion

Procedures

imaging

Body systems

Oncology